Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Huiying Sun

Showing results (201-210 of 211) with videos related to

Pageof 22
Sort By:
Cancer Science|September 27, 2024
Dynamic single-cell sequencing unveils the tumor microenvironment evolution of gastric cancer abdominal wall metastases during radiotherapyQianqian Mao, Zhenzhen Wu, Yonghong Lai, et al.
Plos One|March 31, 2023
Mapping EQ5D utilities from forced vital capacity and diffusing capacity in fibrotic interstitial lung diseaseAlyson W Wong, Huiying Sun, Ingrid A Cox, et al.
Science Translational Medicine|September 4, 2020
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint componentsMonique B Nilsson, Huiying Sun, Jacqulyne Robichaux, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|May 28, 2025
Immunotyping the Tumor Microenvironment Reveals Molecular Heterogeneity for Personalized Immunotherapy in CancerDongqiang Zeng, Yunfang Yu, Wenjun Qiu, et al.
Nature Medicine|April 25, 2018
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancerJacqulyne P Robichaux, Yasir Y Elamin, Zhi Tan, et al.
Nature Cancer|February 5, 2022
Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapseFan Yang, Samuel W Brady, Chao Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2018
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i>-Mutant NSCLCXiuning Le, Sonam Puri, Marcelo V Negrao, et al.
Science Translational Medicine|November 10, 2017
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockersMonique B Nilsson, Huiying Sun, Lixia Diao, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|October 29, 2025
Predicting Immunotherapy Outcomes in NSCLC Using RNA and Pathology from Multicenter Clinical TrialsZhaojun Wang, Yiran Fang, Xiatong Huang, et al.
Med (New York, N.Y.)|August 1, 2024
Tumor microenvironment RNA test to predict immunotherapy outcomes in advanced gastric cancer: The TIMES001 trialMin Shi, Dongqiang Zeng, Huiyan Luo, et al.
Pageof 22

Showing results (201-210 of 211) with videos related to

Sort By:
Pageof 22
Cancer Science|September 27, 2024
Dynamic single-cell sequencing unveils the tumor microenvironment evolution of gastric cancer abdominal wall metastases during radiotherapyQianqian Mao, Zhenzhen Wu, Yonghong Lai, et al.
Plos One|March 31, 2023
Mapping EQ5D utilities from forced vital capacity and diffusing capacity in fibrotic interstitial lung diseaseAlyson W Wong, Huiying Sun, Ingrid A Cox, et al.
Science Translational Medicine|September 4, 2020
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint componentsMonique B Nilsson, Huiying Sun, Jacqulyne Robichaux, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|May 28, 2025
Immunotyping the Tumor Microenvironment Reveals Molecular Heterogeneity for Personalized Immunotherapy in CancerDongqiang Zeng, Yunfang Yu, Wenjun Qiu, et al.
Nature Medicine|April 25, 2018
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancerJacqulyne P Robichaux, Yasir Y Elamin, Zhi Tan, et al.
Nature Cancer|February 5, 2022
Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapseFan Yang, Samuel W Brady, Chao Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2018
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i>-Mutant NSCLCXiuning Le, Sonam Puri, Marcelo V Negrao, et al.
Science Translational Medicine|November 10, 2017
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockersMonique B Nilsson, Huiying Sun, Lixia Diao, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|October 29, 2025
Predicting Immunotherapy Outcomes in NSCLC Using RNA and Pathology from Multicenter Clinical TrialsZhaojun Wang, Yiran Fang, Xiatong Huang, et al.
Med (New York, N.Y.)|August 1, 2024
Tumor microenvironment RNA test to predict immunotherapy outcomes in advanced gastric cancer: The TIMES001 trialMin Shi, Dongqiang Zeng, Huiyan Luo, et al.
Pageof 22